PubRank

Jörg B Schulz

Author PubWeight™ 136.14‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 PML in a patient treated with fumaric acid. N Engl J Med 2013 3.87
2 Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet 2004 2.75
3 Early outcome of carotid angioplasty and stenting with and without cerebral protection devices: a systematic review of the literature. Stroke 2003 2.63
4 Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6. EMBO J 2009 2.37
5 Repetitive bilateral arm training and motor cortex activation in chronic stroke: a randomized controlled trial. JAMA 2004 2.36
6 Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet 2005 2.28
7 Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurol 2013 2.24
8 Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol 2004 2.15
9 Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J 2009 2.09
10 Systematic review of early recurrent stenosis after carotid angioplasty and stenting. Stroke 2004 2.04
11 Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest 2004 1.92
12 Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002 1.79
13 Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res 2004 1.76
14 Short and long-term motor skill learning in an accelerated rotarod training paradigm. Neurobiol Learn Mem 2004 1.72
15 Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. J Neurosci 2002 1.72
16 Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting. Science 2008 1.67
17 Transgenic rat model of Huntington's disease. Hum Mol Genet 2003 1.66
18 Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 2004 1.61
19 TDP-43-mediated neuron loss in vivo requires RNA-binding activity. PLoS One 2010 1.58
20 Clinical predictors of transient ischemic attack, stroke, or death within 30 days of carotid angioplasty and stenting. Stroke 2005 1.53
21 The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms. Circulation 2012 1.50
22 Deep brain stimulation. Cell Tissue Res 2004 1.42
23 Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc Natl Acad Sci U S A 2007 1.41
24 Penguins and hummingbirds: midbrain atrophy in progressive supranuclear palsy. Neurology 2006 1.40
25 Motor skill learning depends on protein synthesis in motor cortex after training. J Neurosci 2004 1.37
26 Mitochondrial protein quality control by the proteasome involves ubiquitination and the protease Omi. J Biol Chem 2008 1.30
27 The multidrug resistance protein 1 (Mrp1), but not Mrp5, mediates export of glutathione and glutathione disulfide from brain astrocytes. J Neurochem 2006 1.28
28 Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. J Neurosci 2008 1.28
29 Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res 2002 1.23
30 Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7). Hum Mutat 2004 1.22
31 Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Hum Mol Genet 2003 1.22
32 Silencing of the Pink1 gene expression by conditional RNAi does not induce dopaminergic neuron death in mice. Int J Biol Sci 2007 1.20
33 Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease. J Neurochem 2006 1.16
34 Depression comorbidity in spinocerebellar ataxia. Mov Disord 2011 1.15
35 Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res 2002 1.15
36 Lesion location alters brain activation in chronically impaired stroke survivors. Neuroimage 2004 1.14
37 Relation between regional functional MRI activation and vascular reactivity to carbon dioxide during normal aging. J Cereb Blood Flow Metab 2003 1.14
38 Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol 2013 1.14
39 Feasibility of prehospital teleconsultation in acute stroke--a pilot study in clinical routine. PLoS One 2012 1.12
40 RET signaling does not modulate MPTP toxicity but is required for regeneration of dopaminergic axon terminals. Proc Natl Acad Sci U S A 2007 1.11
41 Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. Neuroimage 2004 1.10
42 Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery. Mol Ther 2011 1.06
43 The mitochondrial chaperone protein TRAP1 mitigates α-Synuclein toxicity. PLoS Genet 2012 1.06
44 Characterization of motor skill and instrumental learning time scales in a skilled reaching task in rat. Behav Brain Res 2004 1.05
45 Glutathione release from cultured brain cells: multidrug resistance protein 1 mediates the release of GSH from rat astroglial cells. J Neurosci Res 2002 1.05
46 Accumulation and clearance of alpha-synuclein aggregates demonstrated by time-lapse imaging. J Neurochem 2008 1.05
47 Comparison of three clinical rating scales in Friedreich ataxia (FRDA). Mov Disord 2009 1.04
48 Influence of SORL1 gene variants: association with CSF amyloid-beta products in probable Alzheimer's disease. Neurosci Lett 2008 1.04
49 Diagnostic challenge and therapeutic dilemma in necrotizing myopathy. Neurology 2013 1.01
50 Investigating function and connectivity of morphometric findings--exemplified on cerebellar atrophy in spinocerebellar ataxia 17 (SCA17). Neuroimage 2012 1.01
51 Co-enzyme Q10 and idebenone use in Friedreich's ataxia. J Neurochem 2013 1.01
52 Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6. Brain 2013 1.00
53 Fas/CD95 regulatory protein Faim2 is neuroprotective after transient brain ischemia. J Neurosci 2011 0.99
54 Blood-based neurochemical diagnosis of vascular dementia: a pilot study. J Neurochem 2007 0.96
55 Parkinson's disease: one biochemical pathway to fit all genes? Trends Mol Med 2002 0.96
56 The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein--implications for Parkinson's disease. FASEB J 2007 0.96
57 The cancer stem cell subtype determines immune infiltration of glioblastoma. Stem Cells Dev 2012 0.95
58 Drosophila melanogaster as a model organism for Alzheimer's disease. Mol Neurodegener 2013 0.95
59 Transient expression of Nxf, a bHLH-PAS transactivator induced by neuronal preconditioning, confers neuroprotection in cultured cells. Brain Res 2007 0.95
60 Palmitoylation is a sorting determinant for transport to the myelin membrane. J Cell Sci 2005 0.94
61 Alternate-form reliability of the Montreal cognitive assessment screening test in a clinical setting. Dement Geriatr Cogn Disord 2012 0.94
62 TRAP1 rescues PINK1 loss-of-function phenotypes. Hum Mol Genet 2013 0.93
63 Spinocerebellar ataxia types 1, 2, 3 and 6: the clinical spectrum of ataxia and morphometric brainstem and cerebellar findings. Cerebellum 2012 0.93
64 Targeted ablation of oligodendrocytes triggers axonal damage. PLoS One 2011 0.93
65 Altered resting-state connectivity in Huntington's disease. Hum Brain Mapp 2013 0.92
66 FasL (CD95L/APO-1L) resistance of neurons mediated by phosphatidylinositol 3-kinase-Akt/protein kinase B-dependent expression of lifeguard/neuronal membrane protein 35. J Neurosci 2005 0.92
67 Cortical stimulation mapping using epidurally implanted thin-film microelectrode arrays. J Neurosci Methods 2006 0.91
68 Chemotherapy-induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity. J Neurochem 2004 0.91
69 CD95/Fas in the brain--not just a killer. Cell Stem Cell 2009 0.91
70 Diffusion-weighted MRI in patients with symptomatic internal carotid artery disease. J Neurol 2002 0.91
71 Neuroanatomic changes and their association with cognitive decline in mild cognitive impairment: a meta-analysis. Brain Struct Funct 2011 0.91
72 Visualization and quantification of disease progression in multiple system atrophy. Mov Disord 2006 0.91
73 Death receptor Fas (CD95) signaling in the central nervous system: tuning neuroplasticity? Trends Neurosci 2008 0.90
74 Tat-Hsp70 protects dopaminergic neurons in midbrain cultures and in the substantia nigra in models of Parkinson's disease. J Neurochem 2007 0.90
75 Statin therapy at carotid angioplasty and stent placement: effect on procedure-related stroke, myocardial infarction, and death. Radiology 2006 0.90
76 Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease. Toxicol Lett 2003 0.90
77 Drosophila as a screening tool to study human neurodegenerative diseases. J Neurochem 2013 0.88
78 Aggregate formation and toxicity by wild-type and R621C synphilin-1 in the nigrostriatal system of mice using adenoviral vectors. J Neurochem 2009 0.88
79 The yeast HtrA orthologue Ynm3 is a protease with chaperone activity that aids survival under heat stress. Mol Biol Cell 2008 0.88
80 Cholesterol depletion reduces aggregation of amyloid-beta peptide in hippocampal neurons. Neurobiol Dis 2006 0.87
81 A30P α-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice. Neurobiol Dis 2011 0.86
82 Magnetic resonance imaging in spinocerebellar ataxias. Cerebellum 2008 0.86
83 Potential synergistic protection of retinal ganglion cells from axotomy-induced apoptosis by adenoviral administration of glial cell line-derived neurotrophic factor and X-chromosome-linked inhibitor of apoptosis. Neurobiol Dis 2002 0.86
84 Transgenic overexpression of the alpha-synuclein interacting protein synphilin-1 leads to behavioral and neuropathological alterations in mice. Neurogenetics 2010 0.85
85 Large-scale screen for modifiers of ataxin-3-derived polyglutamine-induced toxicity in Drosophila. PLoS One 2012 0.85
86 Monitoring progression in Friedreich ataxia (FRDA): the use of clinical scales. J Neurochem 2013 0.85
87 Protein synthesis inhibition blocks consolidation of an acrobatic motor skill. Learn Mem 2004 0.85
88 Clinical significance of post-interventional cerebral hyperdensities after endovascular mechanical thrombectomy in acute ischaemic stroke. Neuroradiology 2013 0.85
89 Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity. Neurobiol Aging 2012 0.84
90 Parkinson's disease and dementia: a longitudinal study (DEMPARK). Neuroepidemiology 2011 0.84
91 Impairment of the septal cholinergic neurons in MPTP-treated A30P α-synuclein mice. Neurobiol Aging 2012 0.83
92 Self-rated health status in spinocerebellar ataxia--results from a European multicenter study. Mov Disord 2010 0.83
93 Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines. J Neurooncol 2012 0.82
94 New developments in diagnosis and treatment of Parkinson's disease--from basic science to clinical applications. J Neurol 2004 0.82
95 Membrane-permeable Bcl-xL prevents MPTP-induced dopaminergic neuronal loss in the substantia nigra. J Neurochem 2007 0.82
96 Adenoviral (full-length) Apo2L/TRAIL gene transfer is an ineffective treatment strategy for malignant glioma. J Neurooncol 2003 0.82
97 Increased brain tissue sodium concentration in Huntington's Disease - a sodium imaging study at 4 T. Neuroimage 2012 0.81
98 Comparison of angioplasty and stenting with cerebral protection versus endarterectomy for treatment of internal carotid artery stenosis in elderly patients. J Vasc Surg 2004 0.81
99 Diminished activation of motor working-memory networks in Parkinson's disease. PLoS One 2013 0.81
100 Novel FHL1 mutation in a family with reducing body myopathy. Muscle Nerve 2012 0.81
101 Early outcome of carotid angioplasty and stenting versus carotid endarterectomy in a single academic center. Cerebrovasc Dis 2003 0.80
102 Neural correlates of impaired emotion processing in manifest Huntington's disease. Soc Cogn Affect Neurosci 2013 0.80
103 Specific and disease stage-dependent episodic memory-related brain activation patterns in Alzheimer's disease: a coordinate-based meta-analysis. Brain Struct Funct 2014 0.80
104 Case reports of PML in patients treated for psoriasis. N Engl J Med 2013 0.79
105 PKC links Gq-coupled receptors to DAT-mediated dopamine release. J Neurochem 2010 0.79
106 Clinical data and characterization of the liver conditional mouse model exclude neoplasia as a non-neurological manifestation associated with Friedreich's ataxia. Dis Model Mech 2012 0.79
107 Ergoline and non-ergoline derivatives in the treatment of Parkinson's disease. J Neurol 2006 0.79
108 Effects of dopamine on the glutathione metabolism of cultured astroglial cells: implications for Parkinson's disease. J Neurochem 2002 0.78
109 Morphological spectrum and clinical features of myopathies with tubular aggregates. Histol Histopathol 2013 0.78
110 Modulation of hippocampal neuroplasticity by Fas/CD95 regulatory protein 2 (Faim2) in the course of bacterial meningitis. J Neuropathol Exp Neurol 2014 0.78
111 Spectrum of phenotypes and genotypes in Parkinson's disease. J Neurol 2002 0.78
112 BAG1 modulates huntingtin toxicity, aggregation, degradation, and subcellular distribution. J Neurochem 2009 0.78
113 Extracellular domain splice variants of a transforming protein tyrosine phosphatase alpha mutant differentially activate Src-kinase dependent focus formation. Genes Cells 2007 0.78
114 150 years of Friedreich ataxia: from its discovery to therapy. J Neurochem 2013 0.77
115 Lewy body dementia and Parkinson's disease with dementia. J Neurol 2008 0.76
116 Differential pattern of brain-specific CSF proteins tau and amyloid-β in Parkinsonian syndromes. Mov Disord 2010 0.76
117 Adjuvant granulocyte colony-stimulating factor therapy results in improved spatial learning and stimulates hippocampal neurogenesis in a mouse model of pneumococcal meningitis. J Neuropathol Exp Neurol 2015 0.76
118 CDK5 protects from caspase-induced Ataxin-3 cleavage and neurodegeneration. J Neurochem 2014 0.76
119 Therapeutic strategies for Parkinson's disease based on data derived from genetic research. J Neurol 2003 0.75
120 Gene dosage-dependent effects of bcl-2 expression on cellular survival and redox status. Free Radic Biol Med 2003 0.75
121 The dopaminergic nigrostriatal system: development, physiology, disease. Cell Tissue Res 2004 0.75
122 Consensus paper: radiological biomarkers of cerebellar diseases. Cerebellum 2015 0.75
123 Teaching neuroimages: combined retinal and cerebral hyperperfusion syndrome after carotid thromboendarterectomy. Neurology 2013 0.75
124 Cognitive effects of deep brain stimulation for essential tremor: evaluation at 1 and 6 years. J Neural Transm (Vienna) 2013 0.75
125 Myopathy with lobulated fibers, cores, and rods caused by a mutation in collagen VI. Neurology 2012 0.75
126 Posterior Cortical Atrophy: A Case Report of a 6-Year Natural Progression. Alzheimer Dis Assoc Disord 2016 0.75
127 Yeast, fish, fly--models to study the pathogenesis of proteinopathies and screen for interventions. J Neurochem 2013 0.75
128 Chronic Subdural Hematoma-Antithrombotics and Thrombotic Complications. Dtsch Arztebl Int 2022 0.75
129 Molecular imaging and its applications: visualization beyond imagination. J Neurochem 2013 0.75
130 Can We Close the Discussion on PFO-Closure? Hellenic J Cardiol 2015 0.75